Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Malaria, Falciparum D016778 22 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Liver Failure D017093 5 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Strongylida Infections D017206 5 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Satouchi K et al. Application of selected ion monitoring to determination of platelet-activating factor. 1983 J. Biochem. pmid:6423622
Hillmar I and Zöllner N Saturated and unsaturated 1-0-alkyl-2-0-acetoyl-sn-glycero-3-phosphocholines and 2-lyso derivatives from ratfish liver oil. Effect on adenosine 3':5'-cyclic monophosphate concentration in hepatocyte suspensions. 1983 Res Exp Med (Berl) pmid:6310713
Mauco G et al. Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets. 1983 FEBS Lett. pmid:6311620
Camussi G et al. Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. 1983 J. Immunol. pmid:6311899
Hwang SB et al. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. 1983 Biochemistry pmid:6313047
Shukla SD and Hanahan DJ An early transient decrease in phosphatidylinositol 4,5-bisphosphate upon stimulation of rabbit platelets with acetylglycerylether phosphorylcholine (platelet activating factor). 1983 Arch. Biochem. Biophys. pmid:6320731
McManus LM et al. Thromboxane B2 (TxB2) release following acetyl glyceryl ether phosphorylcholine (AGEPC) infusion in the rabbit. 1983 Immunopharmacology pmid:6832960
Otsuka A et al. alpha-Adrenergic blocking action of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats. 1983 Clin Exp Hypertens A pmid:6133661
Jouvin-Marche E et al. Effect of the Ca2+ antagonist nifedipine on the release of platelet-activating factor (PAF-acether), slow-reacting substance and beta-glucuronidase from human neutrophils. 1983 Eur. J. Pharmacol. pmid:6134631
Sano K et al. A role of calcium-activated phospholipid-dependent protein kinase in human platelet activation. Comparison of thrombin and collagen actions. 1983 J. Biol. Chem. pmid:6218169
Vargaftig BB et al. Synergized activation of human platelets by epinephrine and platelet-activating factor-acether is adenosine diphosphate and thromboxane A2-independent. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221558
Voelkel NF et al. Platelet-activating factor causes pulmonary vasoconstriction and edema via platelet-independent leukotriene formation. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221590
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Bessin P et al. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. 1983 Eur. J. Pharmacol. pmid:6687572
Mueller HW et al. 1-O-alkyl-linked phosphoglycerides of human platelets: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. 1983 Lipids pmid:6419001
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Roussi J et al. [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. 1983 Nouv Rev Fr Hematol pmid:6622253
Valone FH and Goetzl EJ Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). 1983 Am. J. Pathol. pmid:6624880
Barradas MA et al. The effect of fenfluramine on collagen-induced platelet aggregation in vitro. 1983 Br J Clin Pharmacol pmid:6626443
Korth R et al. 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholines: influence on aggregation and [3H]serotonin release of human thrombocytes. 1983 Chem. Phys. Lipids pmid:6627525
Moschidis MC et al. Phosphono-platelet activating factor I. Synthesis of 1-O-hexadecyl-2-O-acetyl-glyceryl-3-(2-trimethyl ammonium-methyl) phosphonate and its platelet activating potency. 1983 Chem. Phys. Lipids pmid:6627527
Heffner JE et al. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. 1983 J. Clin. Invest. pmid:6822668
Randolph AE et al. Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats. 1983 Clin Exp Hypertens A pmid:6684006
Morley J et al. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. 1983 Br. J. Pharmacol. pmid:6685552
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Garcia Gil M and Sanchez Crespo M Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. 1983 Immunopharmacology pmid:6654649
Tokumura A et al. Biphasic action of platelet-activating factor on isolated guinea-pig ileum. 1983 Lipids pmid:6656539
Hamasaki Y et al. [Effects of platelet activating factor (PAF:AGEPC) on airway and pulmonary vascular constriction of guinea pigs--with special reference to the relation with TXA2]. 1983 Kokyu To Junkan pmid:6658209
Björk J et al. Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. 1983 Acta Physiol. Scand. pmid:6659994
Björk J and Smedegård G Acute microvascular effects of PAF-acether, as studied by intravital microscopy. 1983 Eur. J. Pharmacol. pmid:6662199
Holt PG et al. Platelet serotonin release by human polymorphonuclear leucocytes stimulated by cotton dust bacteria. 1983 Clin. Exp. Immunol. pmid:6831770
McDonald TP and Kalmaz GD Effects of thrombopoietin on the number and diameter of marrow megakaryocytes of mice. 1983 Exp. Hematol. pmid:6832243
Lewis JC et al. Platelet-activating factor effects on pulmonary ultrastructure in rabbits. 1983 Exp. Mol. Pathol. pmid:6832335
Levy JV Calmodulin antagonists inhibit aggregation of human, guniea pig and rabbit platelets induced with platelet activating factor. 1983 FEBS Lett. pmid:6832368
Touqui L et al. Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite. 1983 Biochem. Biophys. Res. Commun. pmid:6838557
Worthen GS et al. Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. 1983 Chest pmid:6839840
Heffner JE et al. Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. 1983 Chest pmid:6839854
Virella G et al. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. 1983 Immunology pmid:6885111
Camussi G et al. Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. 1983 Immunopharmacology pmid:6885382
O'Flaherty JT and Wykle RL Biology and biochemistry of platelet-activating factor. 1983 Clin Rev Allergy pmid:6370406
Tiffany ML Technical considerations for platelet aggregation and related problems. 1983 Crit Rev Clin Lab Sci pmid:6370596
Vermylen J et al. Normal mechanisms of platelet function. 1983 Clin Haematol pmid:6301715
Camussi G et al. The release of platelet-activating factor from human endothelial cells in culture. 1983 J. Immunol. pmid:6415166
Bonnet J et al. Dependency of the Paf-acether induced bronchospasm on the lipoxygenase pathway in the guinea-pig. 1983 Prostaglandins pmid:6419289